Anurag Maheshwari, MD, on telaprevir-based HCV treatment
June 7, 2013
ORLANDO, Fla. — Anurag Maheshwari, MD, transplant hepatologist at the Institute for Digestive Health and Liver Disease at Mercy Medical Center in Baltimore, discusses his poster, “Sa1059: The Experience with Telaprevir-Based HCV Therapy in Community Practice Does Not Mirror the Clinical Trials Data,” at Digestive Disease Week 2013.
Maheshwari notes that the morbidity associated with telaprevir-based treatment is much greater in real-world practice than had been indicated previously. He urges caution among clinicians in the administration of telaprevir, and stresses the need for rigorous side-effect management protocol and adequate long-term follow-up for patients with HCV receiving this treatment.
Full Story »
Headlines
HCV treatment improves survival among anemic patients
June 6, 2013
High serum ferritin not predictive of advanced fibrosis in NAFLD
June 5, 2013
Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin
June 4, 2013
No comments:
Post a Comment